Detection of Local Relapse of Prostate Cancer With 18F-PSMA-1007.

Published on Jun 1, 2019in Clinical Nuclear Medicine6.587
· DOI :10.1097/RLU.0000000000002543
Robert Seifert10
Estimated H-index: 10
,
Darius Schafigh1
Estimated H-index: 1
+ 2 AuthorsKambiz Rahbar22
Estimated H-index: 22
Sources
Abstract
: Prostate-specific membrane antigen (PSMA)-targeted PET/CT has become a fundamental tool in the management of patients with prostate cancer, especially to rule out local recurrence after surgery or radiation. However, the assessment of the prostatic fossa is difficult due to the renal excretion of PSMA-targeted radionuclides. PET/CT studies using Ga-PSMA-11 PET/CT and F-PSMA-1007 of a 61-year-old man after radical prostatectomy are presented. This case illustrates that F-PSMA-1007 is an ideal radionuclide for the detection of local recurrence of prostate cancer and is superior to Ga-PSMA-11, especially in case of pelvic lesions.
📖 Papers frequently viewed together
2020
31 Citations
17 Citations
References7
Newest
#1Kambiz RahbarH-Index: 22
#2Ali Afshar-Oromieh (University Hospital Heidelberg)H-Index: 37
Last. Matthias WeckesserH-Index: 29
view all 7 authors...
Purpose The introduction of ligands targeting prostate-specific membrane antigen (PSMA), especially 68Ga-PSMA-11, has changed the management of patients with prostate cancer (PCa). 18F-Labelled ligands can be produced in larger amounts and therefore can improve availability for a larger group of patients. The aim of this study was to evaluate the diagnostic performance of the recently introduced 18F-PSMA-1007 in patients with recurrent PCa.
56 CitationsSource
39 CitationsSource
#1Nicholas M. Donin (UCLA: University of California, Los Angeles)H-Index: 15
#2Robert E. Reiter (UCLA: University of California, Los Angeles)H-Index: 66
: Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is highly expressed on prostate adenocarcinomas, exhibits only limited expression in benign and extraprostatic tissues, and thus represents an ideal target for the diagnosis and management of prostate cancer. Since its discovery over 30 y ago, significant effort has been made to develop clinical technology targeting PSMA. The last 5 y have seen an explosion of development of new agents targeting PSMA for diagnostic ...
15 CitationsSource
#1Philipp Backhaus (WWU: University of Münster)H-Index: 3
#2Benjamin NotoH-Index: 5
Last. Kambiz RahbarH-Index: 22
view all 10 authors...
Background Prostate-specific membrane antigen (PSMA) is the up-and-coming target for molecular imaging of prostate cancer. Despite its name, non-prostate-related PSMA expression in physiologic tissue as well as in benign and malignant disease has been reported in various publications. Unlike in prostate cancer, PSMA expression is only rarely observed in non-prostate tumor cells. Instead, expression occurs in endothelial cells of tumor-associated neovasculature, although no endothelial expression...
67 CitationsSource
#1Sara Sheikhbahaei (Johns Hopkins University)H-Index: 33
#2Ali Afshar-Oromieh (University Hospital Heidelberg)H-Index: 37
Last. Steven P. Rowe (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 32
view all 12 authors...
Background The rapidly expanding clinical adaptation of prostate-specific membrane antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has placed an increasing onus on understanding both the potential pearls of interpretation as well as limitations of this new technique. As with any new molecular imaging modality, accurate characterization of abnormalities on PSMA-targeted PET imaging can be accomplished only if one is aware of the normal distribution pattern, ...
144 CitationsSource
#1Kambiz RahbarH-Index: 22
#2Matthias WeckesserH-Index: 29
Last. Martin BögemannH-Index: 18
view all 8 authors...
We evaluated the diagnostic value and accuracy of prostate-specific membrane antigen (PSMA) PET for the intraprostatic delineation of prostate cancer before prostatectomy.We identified 6 patients with biopsy-proven high-risk prostate cancer who were referred for (68)Ga-PSMA PET/CT before radical prostatectomy to rule out metastasis. After prostatectomy, a histologic map of the prostate was reconstructed. The histologic extent and Gleason score of each segment of the prostate were compared with (...
97 CitationsSource
Purpose Positron emission tomography (PET) with choline tracers has found widespread use for the diagnosis of prostate cancer (PC). However, choline metabolism is not increased in a considerable number of cases, whereas prostate-specific membrane antigen (PSMA) is overexpressed in most PCs. Therefore, a 68Ga-labelled PSMA ligand could be superior to choline tracers by obtaining a high contrast. The aim of this study was to compare such a novel tracer with standard choline-based PET/CT.
673 CitationsSource
Cited By8
Newest
#1Nasim Vahidfar (Tehran University of Medical Sciences)H-Index: 3
#2Elisabeth EppardH-Index: 9
Last. Hojjat AhmadzadehfarH-Index: 36
view all 6 authors...
Radiometal-based theranostics or theragnostics, first used in the early 2000s, is the combined application of diagnostic and therapeutic agents that target the same molecule, and represents a considerable advancement in nuclear medicine. One of the promising fields related to theranostics is radioligand therapy. For instance, the concepts of targeting the prostate-specific membrane antigen (PSMA) for imaging and therapy in prostate cancer, or somatostatin receptor targeted imaging and therapy in...
Source
#1Ian Alberts (University of Bern)H-Index: 10
#2Robert Seifert (DKFZ: German Cancer Research Center)
Last. Ali Afshar-Oromieh (University of Bern)H-Index: 37
view all 4 authors...
Prostate-specific membrane antigen-PET/computed tomography (PSMA-PET/CT) is the investigation of choice for imaging prostate cancer. Demonstrating high diagnostic accuracy, PSMA-PET/CT detects disease at very early stages of recurrence, where the chances of a definitive cure may be at their greatest. A number of PSMA-radioligands are in established clinical routine, and there are currently only limited data and no single tracer can clearly be advocated over the others at present. Further clinica...
Source
#1Robert SeifertH-Index: 10
#2Ian AlbertsH-Index: 10
Last. Kambiz RahbarH-Index: 22
view all 4 authors...
Prostate-specific membrane antigen (PSMA) has been the subject of numerous studies within the last 3 decades. PSMA-targeted imaging and therapy have significantly changed the management of patients with prostate cancer in various disease stages, especially in advanced metastasized castration-resistant prostate cancer. Lutetium-177-conjugated PSMA-617 or PSMA-I&T (Lu-PSMA) has shown promising results in multicenter retrospective and monocenter prospective trials. The aim of this review is to prov...
Source
#1Robert W Foley (United Hospitals)H-Index: 8
#2Stewart Redman (United Hospitals)H-Index: 3
Last. David Little (United Hospitals)H-Index: 4
view all 5 authors...
Prostate-specific membrane antigen (PSMA)-based positron-emission tomography (PET)-computed tomography (CT) has shown great promise in prostate cancer imaging. This technique has demonstrated particular utility in the staging of high-risk primary cancer and in the localisation of recurrent disease. The use of fluorine-18 PSMA-1007 is advantageous, as it is excreted via the hepatobiliary system rather than urinary and the longer half-life of fluorine-18 compared to gallium tracers, allows for PSM...
3 CitationsSource
#1Fahad MarafiH-Index: 7
#2Arun SasikumarH-Index: 11
Last. Sanjay ThuruthelH-Index: 1
view all 4 authors...
A 72-year-old man, who is known with a case of metastatic carcinoma of the breast, was referred for F-PMSA 1007 PET/CT with clinical suspicion of synchronous prostate cancer. F-PSMA 1007 PET/CT scan detected no abnormal tracer concentrating lesion in the prostate gland; however, abnormal tracer concentration was noted in soft tissue lesions in left breast, metastatic lymph nodes, and skeletal lesions. Compared with F-FDG PET/CT, more bone lesions were detected on F-PSMA 1007 imaging. The finding...
2 CitationsSource
#1Fahad MarafiH-Index: 3
#1Fahad MarafiH-Index: 7
Last. Wael FathallahH-Index: 3
view all 4 authors...
A 64-year-old woman with metastatic breast cancer on follow-up had suspicious recurrent brain metastases. She underwent F-FDG PET/CT, F-PSMA 1007 brain PET/CT, and brain MRI. F-PSMA 1007 showed intense tracer localization in the suspected recurrent brain metastasis in right parietal lobe and also picked up 2 more metastatic brain lesions, which had concurrent findings of metastasis in subsequent MRI. Our case highlights the feasibility of F-PSMA 1007 PET/CT imaging of brain metastases from nonpr...
6 CitationsSource
#1Fahad MarafiH-Index: 7
#1Fahad MarafiH-Index: 3
Last. Abdulredh EsmailH-Index: 1
view all 4 authors...
: A 64-year-old man with a known case of right parietal lobe glioblastoma multiforme operated on in August 2018 was referred for F-FDG PET/CT with a clinical suspicion of recurrence. He underwent F-FDG and F-PSMA 1007 scans. Both the scans showed intense tracer uptake in right parietal lobe lesion, which concurred with MRI findings of recurrent disease and was later proven on histopathologic examination as recurrence. Our case highlights the feasibility of F-PSMA 1007 PET/CT imaging of suspected...
8 CitationsSource
#1Nasim Vahidfar (Tehran University of Medical Sciences)H-Index: 3
#2Maryam Fallahpoor (Tehran University of Medical Sciences)H-Index: 2
Last. Hojjat Ahmadzadehfar (University Hospital Bonn)H-Index: 36
view all 5 authors...
Many efforts have been made to introduce an appropriate radiopharmaceutical as a theranostic agent for metastatic castration-resistant prostate cancer. Prostate-specific membrane antigen (PSMA) is expressed in most types of prostate cancer (PCa), with only 5–10% of primary PCa lesions being PSMA-negative. When radiolabeled, PSMA tracers show outstanding features in terms of their theranostic properties. In this study, we discuss the pharmacological and physical characteristics of various radioph...
7 CitationsSource